DexCom, Inc. $DXCM Shares Acquired by World Investment Advisors

World Investment Advisors lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 42.5% during the first quarter, HoldingsChannel.com reports. The fund owned 92,737 shares of the medical device company’s stock after purchasing an additional 27,648 shares during the quarter. World Investment Advisors’ holdings in DexCom were worth $5,824,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in DexCom during the 4th quarter worth $483,356,000. AQR Capital Management LLC raised its holdings in shares of DexCom by 597.8% in the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after buying an additional 2,658,158 shares during the last quarter. Holocene Advisors LP purchased a new stake in shares of DexCom in the third quarter valued at about $163,964,000. CIBC Private Wealth Group LLC boosted its stake in shares of DexCom by 374.3% during the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after buying an additional 2,294,709 shares during the period. Finally, Employees Provident Fund Board acquired a new stake in shares of DexCom during the fourth quarter worth about $145,352,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DXCM. BTIG Research restated a “buy” rating and issued a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Piper Sandler reaffirmed an “overweight” rating and set a $88.00 price objective (up from $75.00) on shares of DexCom in a research report on Monday, June 15th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 price objective on shares of DexCom in a research report on Monday, June 8th. Sanford C. Bernstein set a $77.00 target price on DexCom in a research note on Friday, May 1st. Finally, Robert W. Baird set a $80.00 target price on DexCom in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $84.88.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares in the company, valued at $7,326,353. This represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock worth $3,343,977 in the last three months. 0.28% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $71.25 on Friday. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The firm’s 50-day simple moving average is $68.31 and its 200-day simple moving average is $68.17. The company has a market cap of $27.49 billion, a price-to-earnings ratio of 30.45, a PEG ratio of 1.17 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.32 earnings per share. As a group, equities research analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.